10 completed, 8 recruiting, 4 unknown, 2 not yet recruiting. 10 Phase 2, 7 Phase 1, 6 Not applicable, 2 Phase 3, 1 Phase 4.
Follow Ovarian Cancer Stage IV: new trials by email Literature Review of Ovarian Cancer Stage IV trials Research Report on Ovarian Cancer Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Not yet recruiting | Latin American Cooperative Oncology Group | 320 | 2026-09-01 | 2026-08-25 | |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NY-ESO-1 Peptide vaccine, Toripalimab-tpzi - Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Phase 2 | Withdrawn | Georgetown University | 2026-09-01 | 2026-10-09 | |
| Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer GPC3 CD146 CAR-T cells - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 80 | 2025-04-29 | 2025-07-16 |
| NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study Olaparib, Bevacizumab, Durvalumab - Ovarian Cancer Stage IV | Phase 2 | Not yet recruiting | British Columbia Cancer Agency | 40 | 2024-11-01 | 2024-10-23 |
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Tart Cherry Juice - Breast Cancer, Breast Cancer Stage I | Phase 2 | Recruiting | University of California, Davis | 86 | 2024-08-15 | 2026-03-04 |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery Acute Normovolemic Hemodilution/ANH - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-02-23 | 2026-04-01 |
| Tumor Microenvironment in Ovarian Cancer Ovarian Cancer Organoids - Ovarian Cancer Stage III, Ovarian Cancer Stage IV | Recruiting | University of Udine | 50 | 2024-01-02 | 2024-02-22 | |
| Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer Artificial Intelligence - Ovarian Cancer Stage III, Ovarian Cancer Stage IV | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 151 | 2023-01-02 | 2025-12-19 |
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Microdevice - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2022-11-01 | 2026-05-18 |
| Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Unknown | Jing Li | 50 | 2022-08-01 | 2023-09-06 | |
| Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy Exercise, Attention Control - Ovarian Cancer, Ovarian Carcinoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 30 | 2022-04-02 | 2026-02-19 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Niraparib - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 4 | Unknown | Seoul National University Hospital | 102 | 2022-01-01 | 2022-01-26 |
| Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy debulking surgery - Ovarian Cancer Stage IV, Lymph Node Metastases | Completed | Seoul National University Hospital | 121 | 2021-06-01 | 2023-06-26 | |
| Prehabilitation in Gynaecological Cancer Patients Physiological intervention, Psychological intervention, Nutritional intervention - Ovarian Cancer, Ovarian Cancer Stage III | Phase 3 | Recruiting | Charles University, Czech Republic | 64 | 2021-03-25 | 2026-09-28 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Phase 1 / Phase 2 | Active not recruiting | CanariaBio Inc. | 54 | 2021-03-17 | 2026-04-06 |
| A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) Neoadjuvant chemotherapy+Durvalumab+Tremelimumab - Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV | Phase 2 | Unknown | Yonsei University | 24 | 2019-07-04 | 2020-09-28 |
| Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer Blood sample collection - Ovarian Cancer Stage IIIC, Fallopian Tube Cancer Stage IIIC | Not applicable | Terminated | Centre Oscar Lambret | 36 | 2019-05-17 | 2026-03-18 |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Two cycles of neoadjuvant chemotherapy - Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV | Phase 3 | Unknown | Seoul National University Hospital | 298 | 2018-12-19 | 2019-12-10 |
| Self-Advocacy Serious Game in Advanced Cancer Strong Together serious game - Ovarian Cancer Stage III, Ovarian Cancer Stage IV | Not applicable | Completed | University of Pittsburgh | 78 | 2018-12-13 | 2023-07-05 |
| Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Retarded IDS (Interval Debulking Surgery), Standard IDS (Interval Debulking Surgery) - Ovarian Cancer Stage IV, Ovarian Cancer Stage IIIC | Not applicable | Completed | ARCAGY/ GINECO GROUP | 211 | 2018-10-19 | 2026-02-10 |
Showing 20 of 28. Sign in to see all of them.
Ovarian Neoplasms (28) · Fallopian Tube Neoplasms (6) · Breast Neoplasms (4) · Endometrial Neoplasms (3) · Stomach Neoplasms (2) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Esophageal Neoplasms (1) · Frailty (1) · Liver Neoplasms (1) · Lymphatic Metastasis (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1) · Prostatic Neoplasms (1) · Soft Tissue Neoplasms (1)
Adnexal Diseases (28) · Endocrine Gland Neoplasms (28) · Endocrine System Diseases (28) · Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Genital Diseases (28) · Genital Diseases, Female (28) · Genital Neoplasms, Female (28) · Gonadal Disorders (28) · Neoplasms (28) · Neoplasms by Site (28) · Ovarian Diseases (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Fallopian Tube Diseases (6)
Carboplatin (4) · Paclitaxel (4) · Bevacizumab (2) · oregovomab (2) · Albumin-Bound Paclitaxel (1) · Artificial Intelligence (1) · Biosimilar Pharmaceuticals (1) · Cisplatin (1) · Cytoreduction Surgical Procedures (1) · Exercise (1) · Positron Emission Tomography Computed Tomography (1) · Psychosocial Intervention (1) · durvalumab (1) · niraparib (1) · olaparib (1)
Seoul National University Hospital (3) · ARCAGY/ GINECO GROUP (2) · CanariaBio Inc. (2) · Brigham and Women's Hospital (1) · British Columbia Cancer Agency (1) · Centre Oscar Lambret (1) · Charles University, Czech Republic (1) · Daiichi Sankyo (1) · Dana-Farber Cancer Institute (1) · Essen Biotech (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Georgetown University (1) · Jing Li (1) · Latin American Cooperative Oncology Group (1) · MTrap, Inc. (1)
United States (7) · South Korea (4) · China (3) · France (3) · Italy (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Colombia (1) · Czechia (1) · Mexico (1) · Netherlands (1) · Spain (1)
Andreas Obermair (1) · Anna Fagotti, Prof (1) · Antonio Gil-Moreno, MD (1) · Christina Dieli-Conwright, PhD (1) · Christopher Nicodemus, MD FACP (1) · David Cibula, prof. (1) · Delphine Hudry, MD (1) · Dennis Chi, MD (1) · Dr Jung KH, MD (1) · Elizabeth Stover, MD, PhD (1) · Eve Rodler, MD (1) · Hee Seung Kim, MD/PhD (1) · Hee Seung Kim, Pf (1)
PMID 31576697, PMID 32375688, PMID 35321888, PMID 35843174, PMID 37637060, PMID 37865397, PMID 39013870, PMID 39013886, PMID 39237158, PMID 40378056, PMID 40464605
R21CA216796 (1)